NCT06563362RecruitingPhase 2
Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell Carcinoma
Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck
Source: ClinicalTrials.gov · Last updated 8 Oct 2026
Brief summary (registry, in English)
Multicentric prospective model-based de-escalation of the elective clinical target volumes (CTV) in radiotherapy of oropharyngeal carcinoma of all stages with the goal to reduce toxicity. The study investigates the feasibility of this approach as measured by the number of expected out-of-field recurrencies based on the individual patient's state of disease progression and risk factors
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 8 Aug 2024
- Start date
- 4 Feb 2025
- Primary completion date
- 30 Sept 2029
- Lead sponsor
- University of Zurich
- Diseases
- Head and neck cancer
- NCT number
- NCT06563362
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 120
- From 4 Feb 2025 to the primary completion date, 30 Sept 2029
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous surgery, chemotherapy or radiotherapy treatment for other head and neck cancers.
- Previous surgery in head and neck region affecting the cervical lymphatic system. Dissection of singular lymph nodes for diagnostic purposes before treatment start is allowed.
Other illness
- Synchronous or previous malignancies. Exceptions are curatively treated basal cell carcinoma or SCC of the skin, or in situ carcinoma of the cervix uteri, low- or intermediate- risk prostate cancer or breast with a progression-free follow-up time of at least 3 years without any remaining disease burden, or other previous malignancy with a progression-free interval of at least 5 years without any remaining active/progressive disease burden regardless whether the treatment is completed or ongoing as a maintenance treatment (e.g. androgen deprivation therapy for prostate cancer).
- Any severe mental or psychic disorder affecting decision making and ability to provide informed consent.
Other
- Multilevel primary tumors extending unambiguously beyond the oropharynx into the oral cavity, naso- or hypopharynx
- Distant metastases detected.
- Pregnancy or breast feeding
Who the study is looking for
- Patients with a newly diagnosed (no pre-treatment) squamous cell carcinoma of the oropharynx (i.e. tonsils, base of tongue, oropharyngeal walls, oropharyngeal surface of epiglottis; ICD-10 codes C01, C09, C10), T1-4, N0-3.
- Treatment with definitive (chemo) radiotherapy planned, with elective irradiation of the lymph nodes.
- Age ≥ 18 years, no upper age limit.
- ECOG performance score \< 3.
- History/physical examination within 30 days prior to study inclusion by head and neck surgeon and/or radiation oncologist.
- FDG-PET scan prior to study inclusion. In case of inability to perform or contra-indication, at least contrast enhanced MRI scan obligatory.
- Participants need to provide informed consent.
- Patients with a newly diagnosed (no pre-treatment) squamous cell carcinoma of the oropharynx (i.e. tonsils, base of tongue, oropharyngeal walls, oropharyngeal surface of epiglottis; ICD-10 codes C01, C09, C10), T1-4, N0-3.
- Treatment with definitive (chemo) radiotherapy planned, with elective irradiation of the lymph nodes.
- Age ≥ 18 years, no upper age limit.
- ECOG performance score \< 3.
- History/physical examination within 30 days prior to study inclusion by head and neck surgeon and/or radiation oncologist.
- FDG-PET scan prior to study inclusion. In case of inability to perform or contra-indication, at least contrast enhanced MRI scan obligatory.
- Participants need to provide informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cantonal Hospital Aarau Coordinator of this site? Confirm its status | Aarau | Switzerland | Recruiting |
| Ospedale Regionale Di Bellinzona Coordinator of this site? Confirm its status | Bellinzona | Switzerland | Recruiting |
| Inselspital Bern Coordinator of this site? Confirm its status | Bern | Switzerland | Recruiting |
| Hôpitaux universitaires de Genève Coordinator of this site? Confirm its status | Geneva | Switzerland | Recruiting |
| Réseau Hospitalier Neuchâtelois Coordinator of this site? Confirm its status | Neuchâtel | Switzerland | Recruiting |
| Kantonsspital Winterthur Coordinator of this site? Confirm its status | Winterthur | Switzerland | Recruiting |
| Zurich University Hospital Coordinator of this site? Confirm its status | Zurich | Switzerland | Recruiting |
Related publications
- Personalized volume de-escalated elective nodal irradiation in oropharyngeal squamous cell carcinoma (DeEscO): a study protocol.Clin Transl Radiat Oncol · 2026 · PMID 42200110
This page is information, not medical advice. Discuss any trial with your doctor.